Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Gliosarcoma 2Glioblastoma 2Brain Neoplasms 2Prostatic Neoplasms 1Pain 1Oligodendroglioma 1Neoplasm Metastasis 1Glioma 1Carcinoma, Renal Cell 1Astrocytoma 1

Interventions

nabiximols 7Morphine 7Fentanyl 7Hydromorphone 6Tapentadol 5Radiotherapy 4Prednisone 3Methadone 3Ketamine 3Duloxetine Hydrochloride 3Calcium Dobesilate 3Calcium 3Analgesia 3Acetaminophen 3cabozantinib 2Zoledronic Acid 2Surveys and Questionnaires 2Sugars 2Radiosurgery 2Pregabalin 2Pain Management 2Oxycodone 2Minocycline 2Letrozole 2Ibuprofen 2Diclofenac 2Dexamethasone 2Cryosurgery 2Calcium Gluconate 2Bupivacaine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pain × tandutinib × Clear all
NCT00390468 2014-05-28

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

National Cancer Institute (NCI)

Phase 2 Completed
18 enrolled 5 charts
Genitourinary

Neoplasm Metastasis, Pain, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡